Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Ovid Therapeutics Presents Study Showing OV329 Doesn't Accumulate in Eyes
Details : OV329 is a next-generation GABA-aminotransferase (GABA-AT) inhibitor being developed as a potential medicine for rare and treatment-resistant forms of epilepsy and seizures.
Product Name : OV329
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Soticlestat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Ovid Therapeutics Reports Takeda’s Phase 3 Study Results for Soticlestat
Details : TAK-935 (soticlestat), an oral CH24H enzyme inhbitor, is being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet syndrome.
Product Name : TAK-935
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Soticlestat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GV101
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Graviton Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Ovid and Graviton Announce Data for OV888/GV101 in Cerebral Cavernous Malformations
Details : OV888 (GV101) is an investigational small molecule capsule, works by inhibiting Rho-associated coiled-coil containing protein kinase 2 receptor for the treatment of cerebral cavernous malformations.
Product Name : OV888
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2024
Lead Product(s) : GV101
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Graviton Bioscience
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Soticlestat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Ligand Pharmaceuticals
Deal Size : $30.0 million
Deal Type : Agreement
Details : Ligand has acquired a 13 percent portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of TAK-935 (soticlestat), being developed by Takeda in two Phase 3 trials for Lennox-Gastaut syndrome and Dravet...
Product Name : TAK-935
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 18, 2023
Lead Product(s) : Soticlestat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Ligand Pharmaceuticals
Deal Size : $30.0 million
Deal Type : Agreement
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
Details : OV329 is a next-generation GABA-aminotransferase inhibitor being developed for the treatment of rare and treatment-resistant forms of epilepsy and seizures, such as seizures associated with tuberous sclerosis complex, infantile spasms, and conditions wit...
Product Name : OV329
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 01, 2023
Lead Product(s) : OV329
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
Details : OV329,, a next-generation GABA-aminotransferase (GABA-AT) inhibitor demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizures.
Product Name : OV329
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : OV329
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Soticlestat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $856.0 million
Deal Type : Termination
Details : Takeda Pharmaceutical secured global rights from Ovid to develop and commercialize the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome and Lennox-Gastaut sy...
Product Name : TAK-935
Product Type : Other Small Molecule
Upfront Cash : $196.0 million
March 30, 2021
Lead Product(s) : Soticlestat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Takeda Pharmaceutical
Deal Size : $856.0 million
Deal Type : Termination
Lead Product(s) : Soticlestat
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress
Details : Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS stu...
Product Name : TAK-935
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 23, 2020
Lead Product(s) : Soticlestat
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Soticlestat
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from signal-finding, pilot Phase 2 open-label ARCADE study and ENDYMION long-term extension study in CDKL5 deficiency disorder (CDD) and Dup15q syndrome (Dup15q) show seizure frequency reduction over time .
Product Name : TAK-935
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 30, 2020
Lead Product(s) : Soticlestat
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gaboxadol
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The presentation will highlight data from the pivotal Phase 3 NEPTUNE trial investigating OV101 (gaboxadol) in Angelman syndrome.
Product Name : OV101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Gaboxadol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable